Johnson & Johnson has brought its bladder cancer drug TAR-200 to the US market, a year after its prospects were dented by a negative phase 3 readout. The novel formulation of the stalwart ...
Turn your Jellyfin or local library into ad-free TV channels you can flip through, complete with schedules, guides, and that ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback